Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 12/20 | 0.54 |
| ▸ | RXRA | P19793 | 8/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490768 | 0.83 | HSD11B1 (0.49) | KIF11HSD11B1 | |
| SCHEMBL12157465 | 0.81 | KIF11 (0.48) | NR1H2NR1H3RXRAKIF11HSD11B1 | |
| SCHEMBL6243674 | 0.80 | KCNH2 (0.50) | NR1H2NR1H3KCNH2 | |
| SCHEMBL2140712 | 0.79 | PTGS2 (0.53) | NR1H2NR1H3RXRAKCNH2 | |
| SCHEMBL25094229 | 0.78 | KIF11 (0.51) | NR1H2NR1H3RXRACYP2C9KIF11 | |
| SCHEMBL547993 | 0.77 | RXRA (0.51) | RXRACYP2C9KIF11KCNH2 | |
| SCHEMBL4517154 | 0.77 | CYP2C9 (0.48) | RXRACYP2C9KIF11 | |
| SCHEMBL1687505 | 0.77 | NR1H2 (0.52) | NR1H2NR1H3KCNH2 | |
| SCHEMBL13239460 | 0.77 | ENPP2 (0.54) | KIF11HSD11B1 | |
| SCHEMBL5831675 | 0.76 | PTGS2 (0.56) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | claimed |
| EP-1893562-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | Merck Frosst Canada Ltd. (CA) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | claimed |
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | disclosed |
| EP-1893562-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | Merck Frosst Canada Ltd. (CA) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MAOB, MAOA, XDH | NR1H2 1720/4885NR1H3 1858/4885RXRA 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.